Trial · NCT01613118
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Urine Protein/Creatinine (Up/C) | RE-021 (Sparsentan) 200, 400, 800 mg Pooled | -44.8 | 95% Confidence Interval -52.7 to -35.7 | percent change | |
| Percent Change in Urine Protein/Creatinine (Up/C) | Irbesartan 300 mg Pooled | -18.5 | 95% Confidence Interval -34.6 to 1.7 | percent change | |
| Percent Change in Urine Protein/Creatinine (Up/C) | RE-021 (Sparsentan) 400 and 800 mg Pooled | -47.4 | 95% Confidence Interval -56.3 to -36.9 | percent change | |
| Percent Change in Urine Protein/Creatinine (Up/C) | RE-021 (Sparsentan) 200mg | -33.1 | 95% Confidence Interval -49.3 to -11.6 | percent change | |
| Percent Change in Urine Protein/Creatinine (Up/C) | RE-021 (Sparsentan) 400mg | -52.7 | 95% Confidence Interval -64.3 to -37.2 | percent change | |
| Percent Change in Urine Protein/Creatinine (Up/C) | RE-021 (Sparsentan) 800mg | -41.3 | 95% Confidence Interval -54.4 to -24.4 | percent change | |
| Percentage of Patients Achieving FSGS Partial Remission Endpoint (FPRE) | RE-021 (Sparsentan) 200, 400, 800 mg Pooled | 28.13 | percentage of patients | ||
| Percentage of Patients Achieving FSGS Partial Remission Endpoint (FPRE) | Irbesartan 300 mg Pooled | 9.38 | percentage of patients | ||
| Percentage of Patients Achieving FSGS Partial Remission Endpoint (FPRE) | RE-021 (Sparsentan) 400 and 800 mg Pooled | 31.37 | percentage of patients | ||
| Percentage of Patients Achieving FSGS Partial Remission Endpoint (FPRE) | RE-021 (Sparsentan) 200 mg | 15.38 | percentage of patients | ||
| Percentage of Patients Achieving FSGS Partial Remission Endpoint (FPRE) | RE-021 (Sparsentan) 400 mg | 38.10 | percentage of patients | ||
| Percentage of Patients Achieving FSGS Partial Remission Endpoint (FPRE) | RE-021 (Sparsentan) 800 mg | 26.67 | percentage of patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01613118/results